Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Breast Neoplasms
/ diagnostic imaging
Cell Proliferation
/ drug effects
Cyclin-Dependent Kinase 4
/ antagonists & inhibitors
Cyclin-Dependent Kinase 6
/ antagonists & inhibitors
Dideoxynucleosides
Estrogen Receptor Antagonists
/ administration & dosage
Female
Fluorine Radioisotopes
Fulvestrant
/ administration & dosage
Humans
Longitudinal Studies
MCF-7 Cells
Mice
Mice, SCID
Piperazines
/ administration & dosage
Positron Emission Tomography Computed Tomography
/ methods
Pyridines
/ administration & dosage
Radiopharmaceuticals
Random Allocation
Receptors, Estrogen
/ antagonists & inhibitors
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 05 2019
15 05 2019
Historique:
received:
24
08
2018
revised:
11
11
2018
accepted:
14
01
2019
pubmed:
30
1
2019
medline:
17
7
2020
entrez:
30
1
2019
Statut:
ppublish
Résumé
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine-therapy have emerged as an important regimen of care for estrogen receptor (ER)-positive metastatic breast cancer, although identifying predictive biomarkers remains a challenge. We assessed the ability of two PET-proliferation tracers, [ To determine the effect of CDK4/6 inhibition combined with estrogen-blockade, we assessed cell proliferation in six breast cancer cell lines after 1, 3, and 6 days of treatment with palbociclib and/or fulvestrant. These data were correlated to All palbociclib-sensitive cell lines showed decreased [ Our data suggest complementary roles of [
Identifiants
pubmed: 30692100
pii: 1078-0432.CCR-18-2769
doi: 10.1158/1078-0432.CCR-18-2769
pmc: PMC9788667
mid: NIHMS1519282
doi:
Substances chimiques
Dideoxynucleosides
0
Estrogen Receptor Antagonists
0
Fluorine Radioisotopes
0
Piperazines
0
Pyridines
0
Radiopharmaceuticals
0
Receptors, Estrogen
0
3',3'-difluoro-3'-deoxythymidine
121353-87-5
Fulvestrant
22X328QOC4
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
palbociclib
G9ZF61LE7G
Fluorine-18
GZ5I74KB8G
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3063-3073Subventions
Organisme : NIBIB NIH HHS
ID : T32 EB004311
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Oncologist. 2017 Sep;22(9):1028-1038
pubmed: 28652278
Endocr Relat Cancer. 2011 Apr 28;18(3):333-45
pubmed: 21367843
J Nucl Med. 2005 Mar;46(3):455-63
pubmed: 15750159
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
BMJ. 2014 Jun 09;348:g3608
pubmed: 24912480
Nucl Med Biol. 2004 Aug;31(6):803-9
pubmed: 15246372
Eur J Pharmacol. 2005 Nov 21;525(1-3):8-17
pubmed: 16289030
J Nucl Med. 2013 Mar;54(3):350-7
pubmed: 23359657
J Clin Oncol. 2010 Apr 1;28(10):1684-91
pubmed: 20194857
Nat Commun. 2017 Jun 27;8:15916
pubmed: 28653662
Eur J Cancer. 2016 Mar;55:81-97
pubmed: 26820682
J Biol Chem. 2000 Dec 8;275(49):38221-9
pubmed: 10991938
Endocr Relat Cancer. 2016 Aug;23(8):R337-52
pubmed: 27406875
Br J Cancer. 2014 Jun 10;110(12):2847-54
pubmed: 24832174
Mol Cell Biol. 2001 Feb;21(3):794-810
pubmed: 11154267
Cancer Res. 2017 May 1;77(9):2488-2499
pubmed: 28249908
Adv Exp Med Biol. 2017;964:49-61
pubmed: 28315264
Clin Cancer Res. 2018 Jul 1;24(13):2999-3004
pubmed: 29437768
Cancer Cell. 2012 Oct 16;22(4):438-51
pubmed: 23079655
J Biol Chem. 2001 May 18;276(20):16617-23
pubmed: 11278443
BMC Clin Pathol. 2012 May 03;12:7
pubmed: 22554285
Eur J Cancer. 2012 Mar;48(4):416-24
pubmed: 22209266
Cancer Res. 1997 Jan 1;57(1):156-61
pubmed: 8988058
PET Clin. 2018 Jul;13(3):445-457
pubmed: 30100082
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
PLoS One. 2013 Sep 20;8(9):e74188
pubmed: 24073202
J Immunol. 1984 Oct;133(4):1710-5
pubmed: 6206131
Mol Endocrinol. 1995 Dec;9(12):1804-13
pubmed: 8614416
Appl Radiat Isot. 2010 Dec;68(12):2268-73
pubmed: 20594864
PLoS One. 2012;7(11):e50618
pubmed: 23226334
J Nucl Med. 2008 Jun;49 Suppl 2:64S-80S
pubmed: 18523066
Curr Protoc Mol Biol. 2015 Jul 01;111:28.6.1-28.6.11
pubmed: 26131851
EJNMMI Radiopharm Chem. 2017;1(1):15
pubmed: 29564391
PLoS One. 2016 Jul 28;11(7):e0159916
pubmed: 27467716
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Oral Oncol. 2005 Apr;41(4):416-22
pubmed: 15792614
Biomed Res Int. 2014;2014:218578
pubmed: 24860813
Breast Cancer Res Treat. 2013 Jun;139(2):539-52
pubmed: 23674192
Br J Cancer. 2007 Jan 29;96(2):231-40
pubmed: 17242697
J Biol Chem. 2012 Aug 17;287(34):29075-87
pubmed: 22733811
Nucl Med Biol. 2016 Nov;43(11):721-731
pubmed: 27589334
Nucl Med Biol. 2004 Oct;31(7):829-37
pubmed: 15464384
Nature. 2007 Feb 8;445(7128):656-60
pubmed: 17251933
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7160-7165
pubmed: 28559337
J Nucl Med. 2015 Nov;56(11):1681-9
pubmed: 26359256
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8072-7
pubmed: 8755605